Jannis Kountouras

List of Publications by Year in descending order

236 papers	7,114 citations	70961 41 h-index	69108 77 g-index
238 all docs	238 docs citations	238 times ranked	7526 citing authors

#	Article	IF	Citations
1	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: Clinical and Experimental, 2019, 92, 82-97.	1.5	679
2	Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. Current Molecular Medicine, 2009, 9, 299-314.	0.6	270
3	Adipokines in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1062-1079.	1.5	250
4	The role of adiponectin in the pathogenesis and treatment of nonâ€alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2010, 12, 365-383.	2.2	220
5	Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology, 2006, 66, 938-940.	1.5	202
6	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, 59, 30-43.	2.9	186
7	Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 207-217.	1.5	179
8	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	1.1	178
9	The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review. Helicobacter, 2011, 16, 79-88.	1.6	175
10	Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism: Clinical and Experimental, 2015, 64, 60-78.	1.5	170
11	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimerâ€™s disease. Journal of Neurology, 2009, 256, 758-767.	1.8	150
12	Extragastric Diseases and Helicobacter pylori. Helicobacter, 2015, 20, 40-46.	1.6	150
13	Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 92-108.	0.6	135
14	Relationship between Helicobacter pylori infection and glaucoma11The authors have no commercial interests in the products or devices mention herein.. Ophthalmology, 2001, 108, 599-604.	2.5	130
15	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2013, 62, 121-126.	1.5	130
16	Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2012, 46, 272-284.	1.1	124
17	Eradication of Helicobacter pylori May Be Beneficial in the Management of Chronic Open-Angle Glaucoma. Archives of Internal Medicine, 2002, 162, 1237.	4.3	103
18	A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. Journal of Cellular and Molecular Medicine, 2005, 9, 196-207.	1.6	97

#	Article	IF	Citations
19	Increased Cerebrospinal Fluid Helicobacter Pylori Antibody in Alzheimerâ€™s Disease. International Journal of Neuroscience, 2009, 119, 765-777.	0.8	96
20	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism: Clinical and Experimental, 2017, 71, 182-197.	1.5	96
21	Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2005, 12, 139-143.	1.7	95
22	Five-year Survival After Helicobacter pylori Eradication in Alzheimer Disease Patients. Cognitive and Behavioral Neurology, 2010, 23, 199-204.	0.5	94
23	Apoptosis in hepatitis C. Journal of Viral Hepatitis, 2003, 10, 335-342.	1.0	90
24	Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?. Helicobacter, 2018, 23, e12454.	1.6	88
25	The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. Current Molecular Medicine, 2012, 12, 68-82.	0.6	85
26	Recent advances in the management of radiation colitis. World Journal of Gastroenterology, 2008, 14, 7289.	1.4	84
27	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism: Clinical and Experimental, 2019, 101, 154005.	1.5	83
28	H. pylori and Parkinsonâ€™s disease: Meta-analyses including clinical severity. Clinical Neurology and Neurosurgery, 2018, 175, 16-24.	0.6	78
29	Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 884-890.	1.0	77
30	Association between Helicobacter pylori infection and mild cognitive impairment. European Journal of Neurology, 2007, 14, 976-982.	1.7	74
31	Alzheimerâ€™s disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Medical Hypotheses, 2007, 68, 378-388.	0.8	71
32	The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2011, 45, 50-54.	1.1	69
33	New Aspects of Helicobacter pylori Infection Involvement in Gastric Oncogenesis. Journal of Surgical Research, 2008, 146, 149-158.	0.8	62
34	Challenge in the Pathogenesis of Autoimmune Pancreatitis: Potential Role of Helicobacter pylori Infection via Molecular Mimicry. Gastroenterology, 2007, 133, 368-369.	0.6	54
35	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism: Clinical and Experimental, 2018, 87, 18-24.	1.5	53
36	Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Medical Hypotheses, 2004, 62, 378-381.	0.8	51

#	Article	IF	Citations
37	Primary open-angle glaucoma: pathophysiology and treatment. Lancet, The, 2004, 364, 1311-1312.	6.3	50
38	Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Journal of Clinical Medicine, 2020, 9, 933.	1.0	48
39	Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Annals of Gastroenterology, 2014, 27, 65-72.	0.4	45
40	Histological Presence of <i>Helicobacter pylori</i> Bacteria in the Trabeculum and Iris of Patients with Primary Open-Angle Glaucoma. Ophthalmic Research, 2012, 47, 150-156.	1.0	44
41	Comment on "The correlation of Helicobacter pylori with the development of cholelithiasis and cholecystitis: the results of a prospective clinical study in Saudi Arabia". European Review for Medical and Pharmacological Sciences, 2016, 20, 3-4.	0.5	44
42	Liver regeneration after hepatectomy. Hepato-Gastroenterology, 2001, 48, 556-62.	0.5	43
43	Effects of combined lowâ€dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, nonâ€invasive indices of steatosis and fibrosis, and adipokine levels in nonâ€alcoholic fatty liver disease: ‹scp›a‹/scp› randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1805-1809.	2.2	41
44	Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. British Journal of Ophthalmology, 2009, 93, 1413-1415.	2.1	40
45	Alzheimerâ€™s disease and gastrointestinal microbiota; impact of ‹i›Helicobacter pylori‹/i› infection involvement. International Journal of Neuroscience, 2021, 131, 289-301.	0.8	38
46	A proposed role of human defensins in Helicobacter pylori-related neurodegenerative disorders. Medical Hypotheses, 2014, 82, 368-373.	0.8	36
47	Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. International Journal of Cardiology, 2017, 229, 17-18.	0.8	36
48	Helicobacter pylori infection and esophageal adenocarcinoma: a review and a personal view. Annals of Gastroenterology, 2017, 31, 8-13.	0.4	33
49	Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. Hormone and Metabolic Research, 2019, 51, 134-140.	0.7	32
50	Guillain-BarrÃ© syndrome. Lancet Neurology, The, 2008, 7, 1080-1081.	4.9	30
51	EFFECT OF HELICOBACTER PYLORI ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: a MR imaging-based pilot open-label study. Arquivos De Gastroenterologia, 2014, 51, 261-268.	0.3	30
52	Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones, 2020, 19, 61-72.	0.9	30
53	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism: Clinical and Experimental, 2020, 104, 154144.	1.5	30
54	Apoptosis, Inflammatory Bowel Disease and Carcinogenesis: Overview of International and Greek Experience. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 249-258.	1.8	29

#	Article	IF	Citations
55	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Annals of Hepatology, 2013, 12, 749-757.	0.6	29
56	Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?. BMC Ophthalmology, 2015, 15, 24.	0.6	29
57	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	1.8	29
58	Reactive oxygen metabolites and upper gastrointestinal diseases. Hepato-Gastroenterology, 2001, 48, 743-51.	0.5	29
59	Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. Journal of Cellular and Molecular Medicine, 2004, 8, 317-328.	1.6	28
60	Helicobacter pylori may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12â€“folate deficiency, and hyperhomocysteinemia sequence. American Journal of Clinical Nutrition, 2007, 86, 805-806.	2.2	27
61	Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1550-1558.	1.5	27
62	Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radical Research, 2017, 51, 73-79.	1.5	26
63	Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetesâ€like approach?. Hepatology, 2018, 68, 389-389.	3.6	26
64	A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection. Annals of the New York Academy of Sciences, 2019, 1452, 12-17.	1.8	26
65	Helicobacter pylori and gastro-oesophageal reflux disease. Lancet, The, 2006, 368, 986.	6.3	25
66	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. Current Molecular Medicine, 2008, 8, 12-37.	0.6	24
67	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Journal of Bone and Mineral Metabolism, 2016, 34, 447-456.	1.3	24
68	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. Annals of Hepatology, 2016, 15, 705-14.	0.6	24
69	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. Journal of Surgical Oncology, 2005, 90, 249-259.	0.8	23
70	The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Current Molecular Medicine, 2018, 17, 389-404.	0.6	23
71	Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity. Helicobacter, 2015, 20, 405-409.	1.6	22
72	Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking. European Archives of Oto-Rhino-Laryngology, 2011, 268, 1169-1174.	0.8	21

#	Article	IF	Citations
73	Impact ofHelicobacter pylorion multiple sclerosis-related clinically isolated syndrome. Acta Neurologica Scandinavica, 2016, 133, 268-275.	1.0	21
74	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	1.9	21
75	Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. Microorganisms, 2020, 8, 894.	1.6	21
76	Association between Helicobacter pylori infection and Guillainâ€BarrÃ© Syndrome: A metaâ€analysis. European Journal of Clinical Investigation, 2020, 50, e13218.	1.7	21
77	Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms, 2021, 9, 2351.	1.6	21
78	Rodent models of obesity. Minerva Endocrinologica, 2020, 45, 243-263.	1.7	20
79	Helicobacter pylori Infection Might Contribute to Esophageal Adenocarcinoma Progress in Subpopulations With Gastroesophageal Reflux Disease and Barrett's Esophagus. Helicobacter, 2012, 17, 402-403.	1.6	19
80	Relationship between infection and multiple sclerosis. Annals of Gastroenterology, 2015, 28, 353-356.	0.4	19
81	Novel aspects of defensinsâ€™ involvement in virus-induced autoimmunity in the central nervous system. Medical Hypotheses, 2017, 102, 33-36.	0.8	18
82	Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 598-602.	0.6	18
83	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-Î³ agonists. Metabolism: Clinical and Experimental, 2017, 66, 64-68.	1.5	17
84	Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle. World Journal of Gastrointestinal Oncology, 2022, 14, 959-972.	0.8	17
85	Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism: Clinical and Experimental, 2019, 96, iii-v.	1.5	16
86	Impact of Helicobacter pylori and/or Helicobacter pyloriâ€“related metabolic syndrome on incidence of allâ€cause and Alzheimerâ€§s dementia. Alzheimer's and Dementia, 2019, 15, 723-725.	0.4	16
87	Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter, 2019, 24, e12588.	1.6	16
88	Comment on â€œEffect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibioticsâ€• World Journal of Gastroenterology, 2017, 23, 6194-6196.	1.4	16
89	Helicobacter pylorimight contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology, 2014, 60, 1450-1451.	3.6	15
90	A prospective analysis of factors influencing fluoroscopy time during therapeutic ERCP. Annals of Gastroenterology, 2012, 25, 338-344.	0.4	15

#	Article	IF	Citations
91	Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepato-Gastroenterology, 2002, 49, 193-7.	0.5	15
92	Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrettâ€™s oesophagus. Medical Hypotheses, 2007, 68, 1174-1175.	0.8	14
93	H pylori infection and reflux oesophagitis. Gut, 2004, 53, 912.	6.1	14
94	Helicobacter pylori and glaucoma. Ophthalmology, 2003, 110, 2433-2434.	2.5	13
95	The effect of mannitol and secretin on the biliary transport of urate in humans. Hepatology, 1996, 23, 229-233.	3.6	12
96	Helicobacter pylori infection as a risk factor for primary open-angle glaucoma. Clinical and Experimental Ophthalmology, 2008, 36, 196-196.	1.3	12
97	Helicobacter pylori Infection and Insulin Resistance. Helicobacter, 2013, 18, 165-166.	1.6	12
98	Helicobacter pylori eradication regimens in an antibiotic highâ€resistance European area: A costâ€effectiveness analysis. Helicobacter, 2020, 25, e12666.	1.6	12
99	Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. Digestive and Liver Disease, 2020, 52, 121-123.	0.4	12
100	Reconsidering the â€œprotectiveâ€•hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Annals of the New York Academy of Sciences, 2020, 1481, 59-71.	1.8	12
101	Apoptosis in hepatocellular carcinoma. Hepato-Gastroenterology, 2003, 50, 242-9.	0.5	12
102	Helicobacter pylori-related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. Ecological Management and Restoration, 2016, 29, 842-842.	0.2	11
103	Active Helicobacter pylori Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence. Gut and Liver, 2017, 11, 733-734.	1.4	11
104	Influence of Helicobacter pyloriâ€connected metabolic syndrome on nonâ€alcoholic fatty liver disease and its related colorectal neoplasm high risk. Liver International, 2020, 40, 475-476.	1.9	11
105	Helicobacter pylori infection as a potential risk factor for multiple sclerosis. Medical Hypotheses, 2020, 143, 110135.	0.8	11
106	Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. Microorganisms, 2021, 9, 1361.	1.6	11
107	New concepts of molecular biology for colon carcinogenesis. Hepato-Gastroenterology, 2000, 47, 1291-7.	0.5	11
108	Impact of Helicobacter pylori and/or Helicobacter pylorirelated metabolic syndrome on gastroesophageal reflux diseaseâ€•Barrett's esophagusâ€•esophageal adenocarcinoma sequence. Helicobacter, 2018, 23, e12534.	1.6	10

#	Article	IF	Citations
109	Does COVID-19 Vaccination Warrant the Classical Principle â€œofelein i mi vlaptinâ€?. Medicina (Lithuania), 2021, 57, 253.	0.8	10
110	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement. Current Molecular Medicine, 2019, 20, 3-12.	0.6	10
111	Eleven-year experience on the endoscopic treatment of post-cholecystectomy bile leaks. Annals of Gastroenterology, 2011, 24, 200-205.	0.4	10
112	New concepts of molecular biology on gastric carcinogenesis. Hepato-Gastroenterology, 2005, 52, 1305-12.	0.5	10
113	Association betweenHelicobacter pyloriburden and Alzheimer's disease. European Journal of Neurology, 2014, 21, e100-e100.	1.7	9
114	The endoscopic morphology of major papillae influences the selected precut technique for biliary access. Gastrointestinal Endoscopy, 2015, 81, 1056.	0.5	9
115	Acute Liver Failure. Journal of Clinical Gastroenterology, 2019, 53, 89-101.	1.1	9
116	Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. Medicina (Lithuania), 2020, 56, 339.	0.8	9
117	The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. Neurochemistry International, 2021, 144, 104938.	1.9	9
118	Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota. European Review for Medical and Pharmacological Sciences, 2019, 23, 1845-1846.	0.5	9
119	The gut-brain axis: interactions between Helicobacter pylori and enteric and central nervous systems. Annals of Gastroenterology, 2015, 28, 506.	0.4	9
120	New epidemiological data on liver oncogenesis. Hepato-Gastroenterology, 2000, 47, 855-61.	0.5	9
121	Apoptosis and autoimmunity as proposed pathogenetic links between Helicobacter pylori infection and idiopathic achalasia. Medical Hypotheses, 2004, 63, 624-629.	0.8	8
122	Impact of <scp>H</scp>elicobacter pylori infection on normal colorectal mucosa, adenomatous polyps and adenocarcinoma sequence. Colorectal Disease, 2014, 16, 390-391.	0.7	8
123	Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. Hormones, 2019, 18, 519-521.	0.9	8
124	Impact of nitric oxide's bidirectional role on glaucoma: focus onHelicobacter pyloriâ€“related nitrosative stress. Annals of the New York Academy of Sciences, 2020, 1465, 10-28.	1.8	8
125	Impact of Helicobacter pyloriâ€linked metabolic syndrome on nonâ€alcoholic fatty liver disease and its connected atrial fibrillation risk. Liver International, 2020, 40, 2036-2037.	1.9	8
126	A fully covered self-expandable metal stent anchored by a 10-Fr double pigtail plastic stent: an effective anti-migration technique. Annals of Gastroenterology, 2016, 30, 114-117.	0.4	8

#	Article	IF	Citations
127	Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepato-Gastroenterology, 1995, 42, 31-6.	0.5	8
128	In Vivo Effect of Omeprazole on HLA-DR Expression and the Nonocyte-Macrophage Function in Patis with Duodenal Ulcer Disease. Immunopharmacology and Immunotoxicology, 1994, 16, 437-448.	1.1	7
129	Aquaporin 4, Helicobacter pylori and potential implications for neuromyelitis optica. Journal of Neuroimmunology, 2013, 263, 162-163.	1.1	7
130	Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Medical Hypotheses, 2014, 82, 795.	0.8	7
131	Helicobacter pylori â€“related metabolic syndrome as predictor ofÂprogression to esophageal carcinoma in a subpopulation-based Barrettâ€™s esophagus cohort. Gastrointestinal Endoscopy, 2017, 85, 462-463.	0.5	7
132	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. Expert Opinion on Pharmacotherapy, 2020, 21, 247-251.	0.9	7
133	infection and gastroesophageal reflux disease - Barrett's esophagus sequence "dilemma". Annals of Gastroenterology, 2015, 28, 153.	0.4	7
134	Factors predicting a positive capsule endoscopy in past overt obscure gastrointestinal bleeding: a multicenter retrospective study. Hippokratia, 2016, 20, 127-132.	0.3	7
135	Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease. Hepato-Gastroenterology, 2000, 47, 1301-4.	0.5	7
136	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis, 2022, 16, 852-862.	0.6	7
137	<scp>H</scp>elicobacter pylori Infection and Serum Adiponectin. Helicobacter, 2013, 18, 321-322.	1.6	6
138	Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening. Gastrointestinal Endoscopy, 2014, 80, 188-189.	0.5	6
139	Helicobacter pylori Associated With Obstructive Sleep Apnea Might Contribute to Sleep, Cognition, and Driving Performance Disturbances in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 1547.	2.4	6
140	A potential impact of Helicobacter pylori infection on both obstructive sleep apnea and atrial fibrillation-related stroke. Sleep Medicine, 2017, 34, 256.	0.8	6
141	Circulating periostin in patients with nonalcoholic fatty liver disease. Endocrine, 2017, 56, 438-441.	1.1	6
142	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579.	0.9	6
143	Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence. American Journal of Gastroenterology, 2018, 113, 1723-1724.	0.2	6
144	Multiple Bidirectionality Brainâ€“Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology, 2018, 155, 1651-1652.	0.6	6

#	Article	IF	Citations
145	Update on the association between nonâ€alcoholic fatty liver disease andHelicobacter pyloriinfection. International Journal of Clinical Practice, 2021, 75, e13737.	0.8	6
146	Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. Metabolism: Clinical and Experimental, 2021, 118, 154736.	1.5	6
147	Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach. Hippokratia, 2012, 16, 347-9.	0.3	6
148	Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites. Anticancer Research, 1993, 13, 2441-5.	0.5	6
149	Active Helicobacter pylori infection on colorectal mucosa â€“ adenomatous polyp â€“ adenocarcinoma sequence. European Journal of Gastroenterology and Hepatology, 2014, 26, 243-244.	0.8	5
150	Circulating homocysteine in nonalcoholic fatty liver disease. European Journal of Internal Medicine, 2015, 26, 152-153.	1.0	5
151	Comparison of digital versus fiberoptic cholangioscopy in patients requiring evaluation of bile duct disease or treatment of biliary stones. Annals of Gastroenterology, 2019, 32, 178-184.	0.4	5
152	Comments to the Editor concerning the paper entitled â€œThe microbiome and ophthalmic diseaseâ€•by Baim etÂal.. Experimental Biology and Medicine, 2019, 244, 430-432.	1.1	5
153	Role of autophagy in gastric carcinogenesis. World Journal of Gastrointestinal Oncology, 2021, 13, 1244-1262.	0.8	5
154	Patients with established gastro-esophageal reflux disease might benefit from eradication. Annals of Gastroenterology, 2014, 27, 352-356.	0.4	5
155	The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review. Archives of Academic Emergency Medicine, 2020, 8, e74.	0.2	5
156	The effect of mannitol and secretin on the biliary transport of urate in humans. Hepatology, 1996, 23, 229-233.	3.6	5
157	Helicobacter pylori and Colorectal Cancer Riskâ€”Letter. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 365-365.	1.1	4
158	Obstructive Sleep Apnea and Environmental Contributors for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1055-1056.	2.4	4
159	Helicobacter pylori might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. Oncogene, 2015, 34, 670-670.	2.6	4
160	Association between cirrhosis and Helicobacter pylori-related brain pathologies. European Journal of Gastroenterology and Hepatology, 2015, 27, 183.	0.8	4
161	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	0.8	4
162	The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. Journal of Neurogastroenterology and Motility, 2019, 25, 473-474.	0.8	4

#	Article	IF	Citations
163	The impact of COVID-19 pandemic on gastrointestinal diseases: a single-center cross-sectional study in central Greece. Annals of Gastroenterology, 2021, 34, 323-330.	0.4	4
164	Helicobacter pylori infection and diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 845-846.	1.8	4
165	Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine. Annals of Gastroenterology, 2019, 32, 318.	0.4	4
166	Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 270-271.	0.5	4
167	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine, 2020, 1, 170-183.	1.5	4
168	infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. Annals of Gastroenterology, 2014, 27, 285.	0.4	4
169	The impact of age on the incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis. Annals of Gastroenterology, 2018, 31, 96-101.	0.4	4
170	Locoregional immunochemotherapy in hepatocellular carcinoma. Hepato-Gastroenterology, 2002, 49, 1109-12.	0.5	4
171	Ofeleein i mi Vlaptinâ€"Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina (Lithuania), 2022, 58, 309.	0.8	4
172	Nonalcoholic fatty liver disease and polycystic ovary syndrome. Annals of Hepatology, 2015, 14, 941-943.	0.6	3
173	Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. Medical Hypotheses, 2016, 95, 34.	0.8	3
174	Eosinophilic Enteritis Initially Presenting as Ampullary Stenosis. Clinical Gastroenterology and Hepatology, 2016, 14, A19-A20.	2.4	3
175	Letter: Helicobacter pylori -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. Alimentary Pharmacology and Therapeutics, 2017, 45, 576-577.	1.9	3
176	Letter: Helicobacter pylori in lean and obese patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 637-638.	1.9	3
177	Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology. Digestive Diseases and Sciences, 2018, 63, 1087-1088.	1.1	3
178	Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. Cellular and Molecular Life Sciences, 2019, 76, 2487-2488.	2.4	3
179	Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. Journal of Clinical Gastroenterology, 2019, 53, 624-626.	1.1	3
180	Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?. Medicina (Lithuania), 2020, 56, 133.	0.8	3

#	Article	IF	Citations
181	Correlation of registered drug packs in Greece with Maastricht V/Florence and Hellenic Helicobacter pylori infection treatment consensuses: A poor or a proper match?. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 6-7.	1.2	3
182	Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. Obesity Surgery, 2021, 31, 1839-1840.	1.1	3
183	Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction. Journal of Neurogastroenterology and Motility, 2021, 27, 147-148.	0.8	3
184	A potential impact of Helicobacter pylori infection on minimal hepatic encephalopathy pathobiology. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 405-412.	0.5	3
185	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. Indian Journal of Psychological Medicine, 2015, 37, 475-476.	0.6	3
186	Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study. Neurology International, 2021, 13, 517-526.	1.3	3
187	Potential impact of Helicobacter pylori-related human Î²-defensin-1 on hepatic encephalopathy and neurodegeneration. Annals of Gastroenterology, 2016, 29, 99.	0.4	3
188	Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al. Heart, 2022, 108, 657.1-657.	1.2	3
189	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. Current Vascular Pharmacology, 2022, 20, 111-113.	0.8	3
190	Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer, 2014, 120, 768-768.	2.0	2
191	ActiveHelicobacter pyloriinfection is associated with colorectal mucosa â€“ adenomatous polyp â€“ early and advanced adenocarcinoma sequence. Scandinavian Journal of Gastroenterology, 2014, 49, 381-382.	0.6	2
192	Additional data on Helicobacter pylori and hepatitis C virus infections and lymphoma association. European Journal of Internal Medicine, 2014, 25, e7-e8.	1.0	2
193	Bone Marrow-Derived Stem Cells in Pathogenesis of Helicobacter pylori -Associated Gastrointestinal Cancer. Clinical and Translational Gastroenterology, 2015, 6, e129.	1.3	2
194	CD44 and Helicobacter pylori-related colon oncogenesis. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1249-1249.	0.5	2
195	Helicobacter pyloriâ€related chronic hepatitis C infection and the risk for cardiovascular disease. Liver International, 2017, 37, 1082-1082.	1.9	2
196	CHAI and MACKâ€3 as noninvasive indices for nonalcoholic steatohepatitis. Liver International, 2019, 39, 1587-1587.	1.9	2
197	Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease. Annals of Gastroenterology, 2019, 32, 214.	0.4	2
198	Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries. International Journal of Environmental Research and Public Health, 2019, 16, 4607.	1.2	2

#	Article	IF	Citations
199	Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity. Hepatobiliary Surgery and Nutrition, 2020, 9, 73-76.	0.7	2
200	A potential impact of Helicobacter pyloriâ€related sarcopenia on severity of portal hypertension. Liver International, 2021, 41, 1168-1169.	1.9	2
201	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. Metabolism: Clinical and Experimental, 2021, 121, 154818.	1.5	2
202	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. Minerva Endocrinology, 2023, 48, .	0.6	2
203	Impact of <scp>Helicobacter pylori</scp>â€related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 407-408.	1.4	2
204	Letter to the Editor Regarding â€œThe Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomyâ€•by Abeid et al.. Obesity Surgery, 2022, 32, 2079.	1.1	2
205	A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients. Liver International, 2014, 34, 1127-1128.	1.9	1
206	Letter: apoptosis and hepatic fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 39, 996-996.	1.9	1
207	Eradication of Helicobacter pylori infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 123.	0.8	1
208	Hepatic encephalopathy (HE) due to intrahepatic portosystemic shunt after total gastrectomy. Digestive and Liver Disease, 2016, 48, 825.	0.4	1
209	Helicobacter pylori infection and oesophageal adenocarcinoma. Cancer Epidemiology, 2016, 42, 206-207.	0.8	1
210	Helicobacter pylorion portal hypertension-related hepatic encephalopathy. Immunopharmacology and Immunotoxicology, 2017, 39, 105-106.	1.1	1
211	Obesity and the nervous system: more questions. Lancet Neurology, The, 2017, 16, 772-773.	4.9	1
212	Potential Impact of Helicobacter pylori Infection on Reflux Disease Sequence. Journal of Clinical Gastroenterology, 2020, 54, 200-201.	1.1	1
213	P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study. Journal of Crohn's and Colitis, 2020, 14, S569-S571.	0.6	1
214	The role of endoscopic ultrasound elastography in differentiating focal liver lesions. European Journal of Gastroenterology and Hepatology, 2020, 32, 1408-1408.	0.8	1
215	In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients. Hepato-Gastroenterology, 1998, 45, 2295-302.	0.5	1
216	Serum visfatin in nonalcoholic fatty liver disease. Annals of Hepatology, 2013, 13, 150-1.	0.6	1

#	Article	IF	Citations
217	Comments on â€œdose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular eventsâ€• Clinical Nutrition, 2022, , .	2.3	1
218	Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2014, 39, 1001-1002.	1.9	0
219	Homocysteine in nonalcoholic steatohepatitis: A reply. European Journal of Internal Medicine, 2016, 35, e40-e41.	1.0	0
220	Potential molecular aspects of Helicobacter pylori-related hyperplastic polyp development and progression. European Journal of Gastroenterology and Hepatology, 2016, 28, 851-852.	0.8	0
221	Comment on â€œTherapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Diseaseâ€• Journal of Immunology, 2018, 200, 3027.1-3027.	0.4	0
222	Current Aspects on Differentiating Relapses from Over-Infections in Symptomatic Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2019, 64, 2686-2687.	1.1	0
223	The relationship between Helicobacter pyloriâ€“related microbiota dysbiosis and gastrointestinal tract pathologies. Scandinavian Journal of Gastroenterology, 2019, 54, 806-807.	0.6	0
224	Letter: Helicobacter pylori in proton pump inhibitorâ€associated biliary disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 313-314.	1.9	0
225	Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. Annals of Hepatology, 2020, 19, 579-580.	0.6	0
226	Letter to the editor re: Li et al. (2020), â€˜The potential role of bacteria in pancreatic cancer: A systematic reviewâ€™. Carcinogenesis, 2020, 41, 539-540.	1.3	0
227	Impact of Helicobacter pylori-related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders. Journal of Neurogastroenterology and Motility, 2021, 27, 653-654.	0.8	0
228	National consensus on Helicobacter pylori infection: the next-day challenge. Annals of Gastroenterology, 2020, 33, 324-325.	0.4	0
229	Letter:Helicobacter pyloriinfection and its role in oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 1215-1216.	1.9	0
230	Should the economic pillar be included in national, European or global consensuses concerning Helicobacter pylori infection treatments?. Annals of Gastroenterology, 2020, 33, 326.	0.4	0
231	Innocent unilateral facial swelling after endoscopic sphincterotomy. Annals of Gastroenterology, 2013, 26, 93.	0.4	0
232	Authors' reply. Annals of Gastroenterology, 2015, 28, 294-295.	0.4	0
233	Locoregional immunochemotherapy in primary and metastatic liver disease: meta-analysis and review of literature. Hepato-Gastroenterology, 2003, 50, 1506-10.	0.5	0
234	Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality. Israel Medical Association Journal, 2018, 20, 725-726.	0.1	0

#	Article	IF	Citations
235	GMâ€CSF as a potential candidate of a vaccineâ€induced reduction ofHelicobacter pyloriinfection. Helicobacter, 2022, 27, e12884.	1.6	0
236	Potential Impact of Active H. pylori Infection-Related Metabolic Syndrome on Preeclampsia Among Pregnant Women [Letter]. International Journal of Women's Health, 0, Volume 14, 845-846.	1.1	0